These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 17344795)
1. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clin Adv Hematol Oncol; 2007 Feb; 5(2):79-81. PubMed ID: 17344795 [No Abstract] [Full Text] [Related]
2. A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Fury MG; Lee NY; Sherman E; Lisa D; Kelly K; Lipson B; Carlson D; Stambuk H; Haque S; Shen R; Kraus D; Shah J; Pfister DG Cancer; 2012 Oct; 118(20):5008-14. PubMed ID: 22415650 [TBL] [Abstract][Full Text] [Related]
3. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426 [TBL] [Abstract][Full Text] [Related]
4. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community. Maguire PD; Meyerson MB; Neal CR; Hamann MS; Bost AL; Anagnost JW; Ungaro PC; Pollock HD; McMurray JE; Wilson EP; Kotwall CA Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):698-704. PubMed ID: 14967423 [TBL] [Abstract][Full Text] [Related]
5. Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer. Kao J; Genden EM; Gupta V; Policarpio EL; Burri RJ; Rivera M; Gurudutt V; Som PM; Teng M; Packer SH Cancer; 2011 Jan; 117(2):318-26. PubMed ID: 20830768 [TBL] [Abstract][Full Text] [Related]
6. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. Garden AS; Harris J; Vokes EE; Forastiere AA; Ridge JA; Jones C; Horwitz EM; Glisson BS; Nabell L; Cooper JS; Demas W; Gore E J Clin Oncol; 2004 Jul; 22(14):2856-64. PubMed ID: 15254053 [TBL] [Abstract][Full Text] [Related]
7. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. Harari PM; Harris J; Kies MS; Myers JN; Jordan RC; Gillison ML; Foote RL; Machtay M; Rotman M; Khuntia D; Straube W; Zhang Q; Ang K J Clin Oncol; 2014 Aug; 32(23):2486-95. PubMed ID: 25002723 [TBL] [Abstract][Full Text] [Related]
8. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Katori H; Tsukuda M; Watai K Cancer Chemother Pharmacol; 2007 Aug; 60(3):399-406. PubMed ID: 17096160 [TBL] [Abstract][Full Text] [Related]
9. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis. Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848 [TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. Budach W; Hehr T; Budach V; Belka C; Dietz K BMC Cancer; 2006 Jan; 6():28. PubMed ID: 16448551 [TBL] [Abstract][Full Text] [Related]
11. Radiation therapy in the management of head-and-neck cancer of unknown primary origin: how does the addition of concurrent chemotherapy affect the therapeutic ratio? Chen AM; Farwell DG; Lau DH; Li BQ; Luu Q; Donald PJ Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):346-52. PubMed ID: 20933340 [TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up. Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029 [TBL] [Abstract][Full Text] [Related]
13. Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules. Moreno-Jiménez M; Valero J; López-Picazo JM; Arbea L; Aristu J; Cambeiro M; Alcalde J; Martínez-Monge R Am J Clin Oncol; 2010 Apr; 33(2):137-43. PubMed ID: 19786847 [TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. Tsao AS; Garden AS; Kies MS; Morrison W; Feng L; Lee JJ; Khuri F; Zinner R; Myers J; Papadimitrakopoulou V; Lewin J; Clayman GL; Ang KK; Glisson BS J Clin Oncol; 2006 Sep; 24(25):4163-9. PubMed ID: 16943532 [TBL] [Abstract][Full Text] [Related]
15. Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. Brizel DM; Esclamado R J Clin Oncol; 2006 Jun; 24(17):2612-7. PubMed ID: 16763273 [TBL] [Abstract][Full Text] [Related]
16. A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced head and neck cancer. Kim B; Dillman RO; Chen P; Hafer R; Cox C; Barth N; Carroll RM; VanderMolen L; Nguyen M; Huang J; Minion A; Plunkett M; Mackintosh R Am J Otolaryngol; 2012; 33(1):93-7. PubMed ID: 21524816 [TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy followed by concurrent chemoradiotherapy in advanced head and neck squamous cell carcinoma. Barone C; Grillo R; Dongiovanni D; Birocco N; Rampino M; Redda MG; Garibaldi E; Munoz F; Pecorari G; Cavalot A; Garzinodemo P; Buffoni L; Ciuffreda L; Ricardi U; Cortesina G; Giordano C; Fasolis M; Berrone S; Bertetto O; Schena M Anticancer Res; 2008; 28(2B):1285-91. PubMed ID: 18505067 [TBL] [Abstract][Full Text] [Related]
18. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256 [TBL] [Abstract][Full Text] [Related]
19. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. Ang KK; Harris J; Garden AS; Trotti A; Jones CU; Carrascosa L; Cheng JD; Spencer SS; Forastiere A; Weber RS J Clin Oncol; 2005 May; 23(13):3008-15. PubMed ID: 15860857 [TBL] [Abstract][Full Text] [Related]
20. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck. Buiret G; Combe C; Favrel V; Pommier P; Martin L; Ecochard R; Fayette J; Tartas S; Ramade A; Céruse P Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):430-7. PubMed ID: 19775831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]